Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inamed Outlines Facial Aesthetic Pipeline; Focuses On Lap-Band Sales Growth

This article was originally published in The Gray Sheet

Executive Summary

Inamed anticipates receiving FDA approval for its Cosmoderm and Cosmoplast tissue engineered human collagen products for wrinkle reduction by year-end

You may also be interested in...



Silicone Breast Implant Return To U.S. Market Heralded By Modular PMA

Inamed likely will be first to the U.S. market with a silicone gel-filled breast implant in the wake of FDA's 1992 call for PMAs for the pre-amendments devices

Inamed Plans Major Training Push To Speed Adoption Of LAP-BAND

Inamed/BioEnterics hopes to have 100 centers trained and qualified to use the LAP-BAND adjustable gastric banding system by the end of 2001.

Health And Wellness Trademark Review 1 December, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel